RCS - Diaceutics PLC - Appointment of VP, Scientific & Medical Services

DiaceuticsAnnouncement

05/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240205:nRSE9422Ba&default-theme=true

RNS Number : 9422B  Diaceutics PLC  05 February 2024

RNS Reach

Diaceutics PLC

Diaceutics Strengthens Leadership Team with appointment of Ken Ruppel as VP of
Scientific and Medical Services

 

Belfast and London, 5 February - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to pharma and biotech companies, is
pleased to announce the appointment of Ken Ruppel as Vice President of
Scientific & Medical Services, effective February 1st 2024.

With a commitment to ensuring every patient has access to the right treatment
at the right time, Diaceutics welcomes Ken to lead the expansion of current
offerings and development of innovative solutions in precision medicine.

Ken joins Diaceutics with an impressive background of over 25 years'
experience delivering commercial and operational success in the medical
research, life sciences, pharmaceutical, biotechnology and clinical diagnostic
markets. He most recently served as VP of Precision Medicine at Amplity
Health, where he played a pivotal role in supporting the launch of over 20
companion diagnostic indications across diverse tumour types and laboratory
methodologies in the US. His strategic expertise was instrumental in guiding
Precision Medicine strategies and tactics for 12 pharmaceutical brands and his
impressive track record showcases his dedication to advancing precision
medicine initiatives.

In his role at Diaceutics, Ken will lead the identification, development and
support of strategic growth opportunities within Scientific & Medical
products and services. His responsibilities will include driving innovation
and leading client interactions.

Ken's passion and expertise in diagnostic enabled therapies will play a
significant role in realising the company's core mission - making precision
medicine globally accessible through the DXRX platform.

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented:

"We are extremely pleased to welcome Ken to Diaceutics as our VP Scientific
and Medical Services. His proven track record in Precision Medicine aligns
seamlessly with our vision, and we are confident in his ability to lead our
Scientific and Medical team to be a driving force towards success."

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500
 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSUFMLELSEFE